A large review of data from 4,646 healthy infants compared two types of inactivated poliovirus vaccines: the Sabin-strain (sIPV) and the Salk-strain (cIPV). The study looked at how well each vaccine helped the body build immunity against different strains of the polio virus.
The results showed that both versions were highly effective. Both the Sabin and Salk strains achieved nearly 100 percent seroconversion rates for three types of poliovirus. While some measurements showed slightly higher antibody levels for the Sabin strain in certain cases, the overall ability to create immunity was comparable between the two.
Regarding safety, both vaccines were found to have acceptable profiles. Some differences were noted: the Salk-strain had more systemic reactions, while the Sabin-strain had slightly more frequent instances of fever and allergic reactions. Because the Sabin-strain requires lower biosafety levels, it may be easier to use in global programs to eliminate polio.
Common questions
How effective is the Sabin-strain vaccine compared to the Salk-strain?
The study found that both vaccines provided comparable protection. For three types of poliovirus, both the Sabin and Salk strains achieved nearly 100% seroconversion rates in infants. While some specific antibody levels were slightly higher for the Sabin strain, the overall ability to create immunity was similar between the two.
Are there different side effects between these two vaccines?
Both vaccines had an acceptable safety profile. However, some differences were noted: the Salk-strain showed more systemic adverse events, while the Sabin-strain was linked to slightly more frequent cases of fever and allergic reactions.
Why does the type of poliovirus vaccine matter?
The Sabin-strain vaccine has lower biosafety requirements than the Salk-strain. This makes it a practical option for global programs aimed at eliminating polio, as it provides comparable immunity while being easier to manage in various settings.
